# Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

> **NCT06780839** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 70 (estimated)

## Conditions studied

- NSCLC, Stage I, II, IIIA, IIIB

## Interventions

- **DRUG:** Ensartinib

## Key facts

- **NCT ID:** NCT06780839
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2029-01-15
- **Final completion:** 2030-01-15
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06780839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06780839, "Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06780839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*